aalto1 untyped-item.component.html
In Vivo Evaluation of Pam2Cys-Modified Cancer-Testis Antigens as Potential Self-Adjuvanting Cancer Vaccines
Loading...
Access rights
openAccess
CC BY
CC BY
Creative Commons license
Except where otherwised noted, this item's license is described as openAccess
publishedVersion
URL
Journal Title
Journal ISSN
Volume Title
A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä
This publication is imported from Aalto University research portal.
View publication in the Research portal (opens in new window)
View/Open full text file from the Research portal (opens in new window)
View publication in the Research portal (opens in new window)
View/Open full text file from the Research portal (opens in new window)
Unless otherwise stated, all rights belong to the author. You may download, display and print this publication for Your own personal use. Commercial use is prohibited.
Date
Department
Major/Subject
Mcode
Degree programme
Language
en
Pages
11
Series
Journal of Peptide Science, Volume 31, issue 6, pp. 1-11
Abstract
Peptide-based vaccines, formulated with an appropriate adjuvant, offer a versatile platform for targeted cancer immunotherapy. While adjuvants are usually coadministered for nucleic acid and protein vaccines, synthetic peptide antigens afford a more effective opportunity to covalently and regioselectively graft immunostimulatory motifs directly onto the antigen scaffold to yield self-adjuvanting vaccines. Herein, we explore the synthesis of two tissue-restricted cancer-testis antigens (CTAs); New York oesophageal cell carcinoma 1 (NY-ESO-1) and B melanoma antigen 4 (BAGE4), both carrying the toll-like receptor (TLR) agonist, Pam2Cys. These constructs were evaluated in vivo along with a lipid nanoparticle (LNP) preparation of the underexplored BAGE4 melanoma antigen.
Description
Publisher Copyright: © 2025 The Author(s). Journal of Peptide Science published by European Peptide Society and John Wiley & Sons Ltd.
Keywords
Other note
Citation
Aljohani, S, Edmonds, AG, Castelletto, V, Seitsonen, J, Hamley, IW, Symonds, P, Brentville, VA, Durrant, LG & Mitchell, NJ 2025, 'In Vivo Evaluation of Pam 2 Cys-Modified Cancer-Testis Antigens as Potential Self-Adjuvanting Cancer Vaccines', Journal of Peptide Science, vol. 31, no. 6, e70022, pp. 1-11. https://doi.org/10.1002/psc.70022